MFN isn't just a pricing debate. It is already changing how pharma companies think about where, when and how they launch new medicines. In this episode of Pharma minds, I speak with Laure Nas de Tourris, Partner at Clarivate, about what she is seeing on the ground as pharma and…
What if Europe’s answer to the rising cost of pharmaceutical innovation wasn’t simply to pay more, but to develop differently? In this episode of Pharma minds, I speak with Franck Le Deu, one of the few European voices with decades of first-hand experience inside Asia’s rapidly evolving biopharma ecosystem. Franck…
👉 L’épisode complet est disponible sur toutes les plateformes d’écoute mais aussi sur Youtube en suivant ce lien : https://youtu.be/HWLSeqH8Yss
What happens when making medicines cheaper in the US makes Europe less attractive for pharmaceutical innovation? In this episode of Pharma minds, I speak with Christoffer Frendesen, a Brussels-based pharmaceutical journalist specializing in pricing and market access, about one of the most consequential questions facing Europe’s pharmaceutical market: what happens…
Ecoutez l'épisode en entier : https://youtu.be/HWLSeqH8Yss
Compléments alimentaires, cosmétiques, huiles essentielles, biocides, laits infantiles… Certains produits se situent à la frontière de plusieurs catégories réglementaires. Et selon leur composition, leur destination ou leur présentation, leur statut peut changer. Dans cet épisode de Pharma minds, je reçois Béatrice Espesson-Vergeat, spécialisée en droit pharmaceutique et réglementaire au cabinet…
The full episode traces the choices, and the ones he didn't make, that led him to Latin America to this new venture : https://youtu.be/m4Bt6C5w_ew
In the full episode, Marc Gailhardou explains how leading in this kind of environment reshaped his approach to risk, to long-term planning, and to what boldness actually requires on the ground : https://youtu.be/G7UjQ9iP1sY
The full Pharma Minds episode explores more of what it takes to lead a biotech, with Marc de Garidel (Abivax) and Paul Bravetti (Brenus Pharma) : https://youtu.be/8tc_eaRO4Yg
The full episode goes further into what 35 years in pharma taught him about choice, chance, and starting over : https://youtu.be/m4Bt6C5w_ew
![[EN] - From managing global subsidiaries to walking the talk : when execution becomes personal](https://i.ytimg.com/vi/m4Bt6C5w_ew/maxresdefault.jpg "[EN] - From managing global subsidiaries to walking the talk : when execution becomes personal")
Organizations demand infinite growth in finite markets. Leaders are left at the crossroads of irreconcilable missions, balancing economic imperatives with the well-being of their teams. What happens when the equation simply has no solution? The cost of execution is sometimes your own breaking point. Welcome to Pharma Minds, Summer Series…
Paul Bravetti raconte les derniers mois de Brenus Pharma dans cette nouvelle édition OFF.
The full Pharma Minds episode goes further into innovation, financing and leadership in biotech, with Marc de Garidel (Abivax) and Paul Bravetti (Brenus Pharma) : https://youtu.be/8tc_eaRO4Yg
![[EN] - Biotech survival and resource allocation : why execution is about choosing what not to do](https://i.ytimg.com/vi/8tc_eaRO4Yg/maxresdefault.jpg "[EN] - Biotech survival and resource allocation : why execution is about choosing what not to do")
You can have the best science in the world, but it means nothing if your company runs out of cash. When resources are limited and markets are unforgiving, execution ceases to be a management theory. It becomes a strict matter of survival. What does it actually cost to fund biotech…
Guillaume Delmotte, qui a passé vingt ans chez Ipsen entre l'Europe, la Russie et la Chine, partage son regard dans ce nouvel épisode OFF.
Listen to the full episode ; https://youtu.be/q7D55Pi5uKs
In the full episode, Marc Gailhardou goes further on what stepping outside a comfort zone taught him about leadership, about resilience, and about why staying too long can be a bigger risk than moving : https://youtu.be/G7UjQ9iP1sY
![[EN] - Trusting the ground : navigating volatility, growth and partnerships across the EEMEA zone](https://i.ytimg.com/vi/G7UjQ9iP1sY/maxresdefault.jpg "[EN] - Trusting the ground : navigating volatility, growth and partnerships across the EEMEA zone")
What do we do when the ground is unstable and information is incomplete? We are told to wait for the right conditions. But what if waiting costs more than acting? The real risk is failing to achieve your purpose. Welcome to Pharma Minds, Summer Series "Executing differently takes courage". I…
Also worth revisiting: our episode with Professor Laurence Faivre on the project's first year in France : https://www.youtube.com/watch?v=XQbkiFQxZY8
Listen to the full episode on Youtube: https://lnkd.in/eVPE5Tkm
Listen to the full episode ; https://youtu.be/q7D55Pi5uKs
![[EN] - The Chinese pharma ecosystem : balancing systemic scale and constant reinvention](https://i.ytimg.com/vi/q7D55Pi5uKs/maxresdefault.jpg "[EN] - The Chinese pharma ecosystem : balancing systemic scale and constant reinvention")
A third of tomorrow's molecules will come from China. Just ten years ago, that figure was three percent. The entire healthcare ecosystem has shifted from a massive potential market into a testing ground for rapid, decentralized execution.The questions goes beyond how to enter this system, but how to keep pace…
Listen to the full episode: https://youtu.be/OS9bMDXg8_Y
